Takeda Pharmaceutical Company has introduced AMAG's iron deficiency anaemia drug, ferumoxytol, in the Europe.
Ferumoxytol is launched as Rienso in Europe and is called as Feraheme in the US.
Both the US and European regulatory bodies have approved the drug as the iron deficiency anemia therapy for adult chronic kidney disease patients, in June 2009 and June 2012 respectively.
AMAG president and chief executive officer William Heiden said the company has four significant organic growth opportunities globally for ferumoxytol and it is advancing in all fronts.
"This first launch in the European Union means patients and physicians there can now benefit from treatment with Rienso. We are very fortunate to have such a committed partner as Takeda for the launch of ferumoxytol in many regions outside of the United States," Heiden added.
Takeda, a European partner of AMAG, will make a $15m milestone payment to AMAG, with the first sale of Rienso in Europe, besides tiered, double-digit royalties on sales in the licensed territories.
